Through an unbiased CRISPR screen in bladder cancer cells, MSH2 has 3 significantly CDDP resistant sgRNA constructs, and the importance of MSH2 is underscored by the fact that cancer cells lacking or expressing a low level of MSH2 lead to chemotherapy insensitivity and worse prognosis [13]. Here, MSH2 is linked to urinary bladder cancer.